Menu
BW CFO World
Community for Finance Professionals, Consultants and allied businesses
  • Home
  • News
  • Videos
  • Articles
    • Credit & Capital
    • Economic Trends
    • Financial Compliance
    • Financial Leadership
    • Financial Management
    • Financial Reporting
    • Financial Strategy
    • Risk Management
    • Taxation
  • Featured
  • Nominate for Awards
Close Menu
20220809_090600
August 9, 2022

Pfizer Buying Spree Continues With $5.4 Bn Hematology Deal

Urvi Srivastava Credit & Capital, Economic Trends Biohaven, Hematology, Pfizer

The latest deal follows Pfizer’s USD 11.6 billion acquisition of Biohaven, which the companies announced in May, and a USD 6.7 billion acquisition of Arena Pharmaceuticals announced last December

Pfizer will spend about USD 5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets for treating sickle cell disease. Oxbryta sales were about $195 million last year.

The latest deal follows Pfizer’s USD 11.6 billion acquisition of Biohaven, which the companies announced in May, and a USD 6.7 billion acquisition of Arena Pharmaceuticals announced last December.

Pfizer also announced in April a smaller acquisition to buy the privately held ReViral Ltd., which is developing a treatment for respiratory syncytial virus.

Pfizer Inc.’s top-selling COVID-19 vaccine and treatment have left the New York City drugmaker flush with cash to spend on an acquisition feel. The vaccine and treatment brought in more than $16 billion combined just in the recently completed second quarter.

Aamir Malik, the company’s chief business innovation officer, told analysts recently that Pfizer was leaving very few stones unturned in looking for expansion opportunities. Malik said Pifzer was looking for deals that will speed up growth in the back half of the decade and can add substantial value either scientifically or commercially.

I think we’re very excited about the opportunities that are ahead of us and the flexibility that our balance sheet gives us to pursue those, he said during a call to discuss second-quarter results.

Pfizer will pay $68.50 per share in cash for each share of Global Blood Therapeutics.

Both companies’ boards have approved the deal, which still needs regulatory approval and approval from GBT shareholders.

Shares of Global Blood Therapeutics Inc., based just outside San Francisco, rose 4% before the opening bell. Shares of Pfizer were essentially flat.

(PTI)

Avatar

Urvi Shrivastav

→ Urvi Shrivastav

Lok Sabha Passes Bill To Promote Use Of Green Energy Reckitt Contributes Rs 7,880 Crore To India’s GDP In 2021

Related Posts

SBI General Insurance CFO

Economic Trends, Financial Leadership, Financial Reporting

CFO Plays Multiple Roles Beyond Finance Sector: CFO, SBI General Insurance

rupee

Economic Trends, Financial Reporting

Rupee Posts 8 Paise Up To 81.60 Against USD Led By Foreign Capital Inflows

economy

Economic Trends, Financial Reporting, Global News

Global Economy May Slowdown More In 2023, According To Big Banks

Selected Stories

  • MayankSynergizing finance, strategy and management: The multipronged role of today’s CFO

    Read more

  • NECNEC Corporation elevates India CFO Mayank Khandelwal to Head of Finance for Global Regional Headquarters and Country Affiliates

    Read more

  • Screenshot 2023-04-18 190754Ramesh Bafna Appointed As The New CFO Of Zepto; Succeeding Jitendra Nagpal

    Read more

  • Screenshot 2023-03-28 180755Infobip appoints Richard Kraska as Chief Financial Officer

    Read more

  • 1494568857_NoPMEQ_CFO-470CFO – From ‘Finance’ To ‘Futuristic’

    Read more

Movements

  • Screenshot 2023-03-28 180755Infobip appoints Richard Kraska as Chief Financial Officer
  • zUah2lDb_400x400Deloitte India Named Romal Shetty As CEO For Four-Year Term
  • cfo imageVishnuhari Pareek Named As Head Of Finance At Arkam Ventures
  • thumbnail_Sidharth1Siddharth Sehgal Is New CFO Of BeatO
  • Business men giving a handshake. Business conceptRamamurthy Becomes MD, CEO of BSE, SEBI approves appointment

Categories

  • Accounting
  • CFO Stance
  • Credit & Capital
  • Economic Trends
  • Featured
  • Financial Compliance
  • Financial Leadership
  • Financial Management
  • Financial Reporting
  • Financial Strategy
  • Financial Technologies
  • Global News
  • Interview
  • Movements
  • Risk Management
  • Taxation

Recent Comments

    Back To Top
    BW CFO World
    • Home
    • News
    • Videos
    • Articles
      • Credit & Capital
      • Economic Trends
      • Financial Compliance
      • Financial Leadership
      • Financial Management
      • Financial Reporting
      • Financial Strategy
      • Risk Management
      • Taxation
    • Featured
    • Nominate for Awards
    © Copyright BW BUSINESSWORLD 2018. All Rights Reserved.